Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 3/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370427 | 0.85 | KIF11 (0.43) | PTGS1PTGS2LMNAKDM4EALDH1A1 | |
| SCHEMBL3370977 | 0.85 | PTGS1 (0.51) | PTGS1PTGS2LMNAKDM4EALDH1A1 | |
| SCHEMBL3371953 | 0.80 | PTGS1 (0.56) | PTGS1PTGS2LMNAKDM4EALDH1A1 | |
| SCHEMBL3373499 | 0.79 | PTGS2 (0.62) | PTGS1PTGS2LMNAKDM4EALDH1A1 | |
| SCHEMBL3371013 | 0.76 | PTGS1 (0.50) | PTGS1PTGS2LMNAKDM4EALDH1A1 | |
| SCHEMBL3915711 | 0.74 | TUBB1 (0.48) | PTGS1PTGS2KDM4EALDH1A1MAPT | |
| SCHEMBL3369796 | 0.73 | PARP1 (0.51) | PTGS1PTGS2LMNAKDM4EALDH1A1 | |
| SCHEMBL3374383 | 0.72 | PTGS2 (0.61) | PTGS1PTGS2LMNAKDM4EALDH1A1 | |
| SCHEMBL3372434 | 0.71 | PTGS1 (0.53) | PTGS1PTGS2LMNAKDM4EALDH1A1 | |
| SCHEMBL19192790 | 0.70 | SMN1; SMN2 (0.53) | PTGS1PTGS2LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656347-B1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2010-10-13 | — | — | EP | disclosed |
| US-7709521-B2 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20060264444-A1 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| EP-1656347-A1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | Astrazeneca AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005019171-A1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264444-A1 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | IDO1, IDO2, TPH1 | PTGS1 179/4885PTGS2 338/4885LMNA 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.